Submit Manuscript  

Article Details

Postoperative Atrial Fibrillation - What Do We Really Know?

[ Vol. 8 , Issue. 4 ]


Maciej Banach, Antonios Kourliouros, Kurt M. Reinhart, Stefano Benussi, Dimitri P. Mikhailidis, Marjan Jahangiri, William L. Baker, Andrea Galanti, Jacek Rysz, John A. Camm, C. Michael White and Ottavio Alfieri   Pages 553 - 572 ( 20 )


Postoperative atrial fibrillation (POAF) is a common complication following cardiac surgery, occurring in 20% to 60% of patients. Advanced age, history of atrial fibrillation (AF), heart failure, peripheral arterial disease and chronic obstructive pulmonary disease are predictors of POAF.

The pathogenesis of AF seems to be multifactorial, and includes electrical and structural remodeling as well as inflammation (a systemic response caused by cardiopulmonary bypass and cardiotomy).

Numerous pharmacologic agents can decrease the incidence of POAF. It is also necessary to evaluate an agents ability to decrease stroke, mortality, length of stay and hospital costs. Currently, the use of beta-blockers with adjunctive amiodarone has been shown to reduce POAF and several of its complications. Two therapeutic choices exist in patients with POAF: rate control and rhythm control. The decision which is more important to target should be based on the symptoms of the individual patient. Unlike in patients with chronic AF, POAF is generally transient, and the risks of anticoagulation may outweigh the benefits.

Surgical ablation techniques and ablation devices have progressed considerably. This made the procedures quicker and simpler, and therefore feasible in virtually all clinical contexts. In turn, this has raised the issue of post-ablation arrhythmias. Although relapsing AF is generally addressed conservatively, it may require ablation, frequently transseptal.

Further research is needed to identify the predictors of POAF and the most effective pharmacological and invasive methods for the prevention and treatment of POAF.


Postoperative atrial fibrillation, predictors, pathogenesis, pharmacotherapy, ablation


Department of Hypertension, Medical University of Lodz, Zeromskiego 113, 90-549 Lodz, Poland.

Read Full-Text article